Try it
Anaesthesia · Complications: malignant hyperthermia mechanism
Sample itemDantrolene treats malignant hyperthermia by acting on which structure?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
C. Ryanodine receptor (RyR1) of the sarcoplasmic reticulum
Dantrolene inhibits RyR1 and reduces calcium release from the sarcoplasmic reticulum, which is the cause of uncontrolled muscle hypermetabolism. The initial dose is 2.5 mg/kg intravenously, repeated to effect up to 10 mg/kg.
Option by option
A. Dihydropyridine receptor
The dihydropyridine receptor is the voltage sensor and is not the target.
B. Nicotinic receptor at the motor end plate
Nicotinic receptors are blocked by neuromuscular blockers.
C. Ryanodine receptor (RyR1) of the sarcoplasmic reticulum (correct)
Correct. Dantrolene blocks the ryanodine receptor.
D. Sodium channel of the sarcolemma
Sodium channels are blocked by local anaesthetics.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More Anaesthesia questions
- Intravenous anaestheticsWhich intravenous anaesthetic agent typically increases heart rate and blood pressure?
- Regional anaesthesiaWhat is the definitive treatment for persistent post-dural puncture headache that does n…
- Inhalational anaestheticsWhich of the following inhalational agents has the lowest MAC, and so the highest potency?
- Pre-operative assessmentA patient with well-controlled mild hypertension and no functional limitation is classif…